• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 433068 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413803420 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413803420 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Sell Off Shares of Halozyme Therapeutics, Down 12.4%

Published on Thu, 01/31/2013 - 11:13
By Peter Chu

Halozyme Therapeutics (NASDAQ:HALO) is one of today's biggest movers, down 12.4% to $6.21. The S&P is trading fractionally lower to 1,501 and the Dow is trading fractionally higher to 13,918.

Halozyme Therapeutics has overhead space with shares priced $6.21, or 37.4% below the average consensus analyst price target of $9.92. The stock should find initial resistance at its 50-day moving average (MA) of $6.61 and further resistance at its 200-day MA of $7.09.

Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $13.50 and is now at $6.21, 61% above that low. The 200-day and 50-day moving averages have moved 0.67% lower and 2.40% higher over the past week, respectively.

Halozyme Therapeutics, Inc. develops and commercializes recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The Company's product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's products offer an alternative to slaughterhouse-derived extracts that carry contamination risks.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

McCormick & Co Earnings Hindsight: Down ...

When McCormick & Co (NYSE:MKC) reported earnings two weeks ago on October 2nd, 2014, an ...

Shares of Strayer Education Have Risen A...

Shares of Strayer Education (NASDAQ:STRA) traded today at $64.79, breaking its 52-week ...

Shares of Sonic Rise Above Previous 52-W...

Shares of Sonic (NASDAQ:SONC) traded today at $23.96, breaking its 52-week high. So fa ...

Shares of Sciclone Pharmaceuticals Rise ...

Shares of Sciclone Pharmaceuticals (NASDAQ:SCLN) traded at a new 52-week high today of ...

Shares of Regeneron Pharmaceuticals Rise...

Regeneron Pharmaceuticals (NASDAQ:REGN) traded today at a new 52-week high of $376.88. ...

Shares of RadNet Have Risen Above Previo...

Shares of RadNet (NASDAQ:RDNT) traded at a new 52-week high today of $8.72. Approximat ...

Recent 52-Week High Exceeded in Shares o...

The Pantry (NASDAQ:PTRY) traded today at a new 52-week high of $24.55. So far today ap ...

Nestle Looks to Continue to Trade Below ...

Shares of Nestle (NASDAQ:NSRGY) traded today at $65.79, breaking its 52-week low. This ...